125 related articles for article (PubMed ID: 16703365)
1. Detection of widespread neurolymphomatosis with 18F-FDG PET.
Oztürk E; Arpaci F; Kocaoğlu M; Arslan N; Bulakbaşi N; Ozgüven M
Eur J Nucl Med Mol Imaging; 2006 Aug; 33(8):975-6. PubMed ID: 16703365
[No Abstract] [Full Text] [Related]
2. Secondary neurolymphomatosis of spinal nerve roots detected by ¹⁸F-FDG PET/CT: a case report and differential diagnosis of the case.
Wang Y; Wang J; Jiang C; Peng Q; Wu M; Ma X
Hell J Nucl Med; 2015; 18(3):261-3. PubMed ID: 26574697
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of neurolymphomatosis with FDG PET.
Rosso SM; de Bruin HG; Wu KL; van den Bent MJ
Neurology; 2006 Aug; 67(4):722-3. PubMed ID: 16924037
[No Abstract] [Full Text] [Related]
4. Neurolymphomatosis on 18F-FDG PET/CT: Diagnosis and Therapy Response.
Gykiere P; Jans L; Degrieck B; Goethals I
Clin Nucl Med; 2016 Feb; 41(2):142-3. PubMed ID: 26402124
[TBL] [Abstract][Full Text] [Related]
5. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
7. Neurolymphomatosis of the peripheral nervous system: a case report and review of the literature.
Sideras PA; Matthews J; Sakib SM; Ofikwu F; Spektor V
Clin Imaging; 2016; 40(6):1253-1256. PubMed ID: 27636384
[TBL] [Abstract][Full Text] [Related]
8. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma.
Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T
J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
10. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
Juweid ME
J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
[No Abstract] [Full Text] [Related]
12. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal lymphomatosis found on 18F-FDG PET/CT.
van Rheenen RW; Bongaerts AH; Glaudemans AW
Eur J Haematol; 2012 Dec; 89(6):503-4. PubMed ID: 22712752
[No Abstract] [Full Text] [Related]
14. Neurolymphomatosis as a late relapse of non-Hodgkin's lymphoma detected by 18F-FDG PET/CT: a case report.
Kajáry K; Molnár Z; Mikó I; Barsi P; Lengyel Z; Szakáll S
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):39-42. PubMed ID: 23683830
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
16. Scintigraphic appearance of "linitis plastica" in a patient with gastric non-Hodgkin's lymphoma on 18F-FDG imaging.
Ak I; Aydemir B; Gülbaş Z
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):625-6. PubMed ID: 16470368
[No Abstract] [Full Text] [Related]
17. 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?
Weber WA
J Nucl Med; 2007 Oct; 48(10):1580-2. PubMed ID: 17909256
[No Abstract] [Full Text] [Related]
18. [Positron emission tomography with 18F-FDG compared with proliferative activity of tumor cells in different subtypes of non-Hodgkin lymphoma].
Tiutin LA; Khodzsibekova MM; Pozharisskiĭ KM; Mukhina MS; Kostenikov NA; Il'in NV
Vopr Onkol; 2011; 57(6):748-52. PubMed ID: 22416392
[TBL] [Abstract][Full Text] [Related]
19. Targeting personalized medicine in a non-Hodgkin lymphoma patient with 18F-FDG and 18F-choline PET/CT.
Ribeiro TH; S R; Castro AC; Paulino E; Mamede M
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):109-111. PubMed ID: 28355370
[TBL] [Abstract][Full Text] [Related]
20. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
